Emphasis on targeted and immunotherapy for liver injury in hepatocellular carcinoma
10.3760/cma.j.cn501113-20230915-00108
- VernacularTitle:重视肝细胞癌靶向及免疫治疗的肝损伤
- Author:
Yuemin NAN
1
;
Lingdi LIU
;
Suxian ZHAO
Author Information
1. 河北医科大学第三医院中西医结合肝病科 河北省慢性肝病肝纤维化研究重点实验室 河北省国际科技合作基地——河北省肝癌分子诊断国际联合研究中心，石家庄 050051
- Keywords:
Hepatocellular carcinoma;
Tyrosine kinase inhibitor;
Antiangiogenic drugs;
Immune checkpoint inhibitor;
Liver injury
- From:
Chinese Journal of Hepatology
2023;31(11):1121-1124
- CountryChina
- Language:Chinese
-
Abstract:
Treatment with molecular targeted drugs and immune checkpoint inhibitors (ICIs) has become the first-line treatment options for unresectable HCC (hepatocellular carcinoma) and is also one of the anti-recurrence therapies of choice for patients at high risk of recurrence following radical treatment. First-line molecular targeted drugs combined with ICIs or dual-immune therapy significantly increase the median overall survival and objective response rate compared to single-targeted drugs. Targeted therapy and immunotherapy are suitable for HCC patients with Child-Pugh classes A~B. Liver damage caused by targeted drugs includes abnormal transaminases and bilirubin and, in severe cases, hypoproteinemia, ascites, and other occurrences. ICIs-associated immune-mediated hepatitis (IMH) mostly occurs within one to three sessions of treatment (4~12 weeks) and can be treated with glucocorticoids. However, immunosuppressants such as mycophenolate mofetil may be used as necessary.Targeted drugs and ICIs with different mechanisms of action can be selected based on the systemic condition and tumor treatment needs following the restoration of normal liver function.
